

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



February 6, 2026

**Consolidated Financial Results for the Nine-Month Period of Fiscal 2025
(Nine-Month Period Ended December 31, 2025) [JGAAP]**

Company name: KAKEN PHARMACEUTICAL CO., LTD.
 Stock exchange listing: Tokyo Stock Exchange
 Securities code number: 4521
 URL: <https://www.kaken.co.jp/english/>
 Representative: Hiroyuki Horiuchi, President and Representative Director
 Contact: Yasuhiko Kondo, General Manager of Accounting & Finance Department
 Telephone: +81-3-5977-5007
 Scheduled date of dividend payment commencement: –
 Supplementary materials for financial results: Yes
 Financial results briefing: None

(Amounts are rounded down to the nearest million yen)

1. Consolidated Financial Results for the Nine-Month Period of Fiscal 2025 (April 1, 2025 to December 31, 2025)

(1) Consolidated Operating Results (cumulative)

(Percentage indicates year-on-year change)

| | Net sales | | Operating profit | | Ordinary profit | | Profit attributable to owners of the parent | |
|----------------------------------|---------------|--------|------------------|--------|-----------------|--------|---|--------|
| | (Million yen) | (%) | (Million yen) | (%) | (Million yen) | (%) | (Million yen) | (%) |
| Nine-Month period of Fiscal 2025 | 57,617 | (24.2) | 554 | (97.8) | 1,172 | (95.5) | 1,398 | (92.7) |
| Nine-Month period of Fiscal 2024 | 75,990 | 39.0 | 25,420 | 186.5 | 26,081 | 180.3 | 19,175 | 187.2 |

Note:

Comprehensive income:

Nine-Month period of Fiscal 2025: ¥ 2,002 million [(89.3)%]

Nine-Month period of Fiscal 2024: ¥ 18,690 million [131.7%]

| | Basic earnings per share | Diluted earnings per share |
|----------------------------------|--------------------------|----------------------------|
| | (Yen) | (Yen) |
| Nine-Month period of Fiscal 2025 | 36.87 | – |
| Nine-Month period of Fiscal 2024 | 506.31 | – |

(2) Consolidated Financial Position

| | Total assets | Net assets | Equity-to-asset ratio |
|-------------------------|---------------|---------------|-----------------------|
| | (Million yen) | (Million yen) | (%) |
| As of December 31, 2025 | 176,440 | 145,808 | 82.6 |
| As of March 31, 2025 | 190,422 | 152,634 | 80.2 |

Reference:

Equity:

As of December 31, 2025: ¥ 145,808 million

As of March 31, 2025: ¥ 152,634 million

2. Cash Dividends

| | Annual dividends per share | | | | |
|--|----------------------------|-------------|-------------|----------|--------|
| | 1st quarter | 2nd quarter | 3rd quarter | Year-end | Total |
| | (Yen) | (Yen) | (Yen) | (Yen) | (Yen) |
| Year ended March 31, 2025 | — | 115.00 | — | 75.00 | 190.00 |
| Year ending March 31, 2026 | — | 95.00 | — | | |
| Year ending March 31, 2026 (Forecast) | | | | 95.00 | 190.00 |

Note: Revisions to the forecast of cash dividends most recently announced: None

* The dividends per share for the 2nd quarter of the year ended March 31, 2025 consist of an ordinary dividend of ¥75.00 and a bonus dividend of ¥40.00.

3. Consolidated Financial Forecast for Fiscal Year Ending March 31, 2026 (April 1, 2025 to March 31, 2026)

(Percentage indicates year-on-year change)

| | Net sales | | Operating profit | | Ordinary profit | | Profit attributable to owners of the parent | | Basic earnings per share |
|-------------------------------|---------------|-------|------------------|--------|-----------------|--------|---|--------|--------------------------|
| | (Million yen) | (%) | (Million yen) | (%) | (Million yen) | (%) | (Million yen) | (%) | (Yen) |
| Year ending March 31, 2026 | 86,300 | (8.2) | 2,100 | (90.0) | 2,800 | (86.8) | 2,300 | (83.5) | 60.74 |

Note: Revisions to the financial forecast most recently announced: None

*** Notes**

(1) Significant changes in the scope of consolidation during the period: None

(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: Yes

(3) Changes in accounting policies, changes in accounting estimates, and restatement

1) Changes in accounting policies due to revisions to accounting standards and other regulations: None

2) Changes in accounting policies other than 1): None

3) Changes in accounting estimates: None

4) Restatement: None

(4) Number of issued shares (common stock)

| | | | | |
|--|----------------------------------|-------------------|----------------------------------|-------------------|
| 1) Number of issued shares at the end of the period (including treasury stock) | As of December 31, 2025 | 44,139,730 shares | As of March 31, 2025 | 45,939,730 shares |
| 2) Number of treasury stock at the end of the period | As of December 31, 2025 | 6,271,390 shares | As of March 31, 2025 | 7,535,854 shares |
| 3) Average number of shares during the period | Nine-Month period of Fiscal 2025 | 37,925,786 shares | Nine-Month period of Fiscal 2024 | 37,872,077 shares |

Note: The number of treasury stock at the end of the period includes the Company's shares held by the "Board Benefit Trust (BBT)" (199,700 shares as of December 31, 2025 and 93,600 shares as of March 31, 2025). The Company's shares held by the BBT are included in the number of treasury stock to be deducted in the calculation of the average number of shares during the period (170,145 shares as of December 31, 2025 and 54,385 shares as of December 31, 2024).

* Review of the Japanese-language originals of the attached quarterly consolidated financial results by certified public accountants or an audit corporation: None

* Explanation of proper use of earnings forecasts, and other special matters:

(Caution regarding forward-looking statements)

The performance forecasts and other descriptions on future events presented in this material are based on information currently available and certain assumptions considered to be reasonable. The actual performance may differ from these forecasts.

How to review the quarterly supplementary material to the financial results reports:

It has been posted on the Company's web site, along with the quarterly financial results reports.

2. Consolidated Financial Results for Nine-Month Period of Fiscal 2025

(1) Consolidated balance sheets

(Millions of yen)

| | Fiscal 2024 (As of March 31, 2025) | Nine-Month period of Fiscal 2025 (As of December 31, 2025) |
|---|---------------------------------------|--|
| Assets | | |
| Current assets | | |
| Cash and deposits | 54,093 | 36,847 |
| Notes and accounts receivable - trade, and contract assets | 21,178 | 24,186 |
| Marketable securities | 15,992 | 8,991 |
| Merchandise and finished goods | 8,805 | 8,626 |
| Work in process | 2,311 | 2,574 |
| Raw materials and supplies | 7,904 | 9,448 |
| Income taxes refund receivable | 120 | 3,333 |
| Other | 970 | 2,513 |
| Allowance for doubtful accounts | (0) | - |
| Total current assets | 111,377 | 96,521 |
| Non-current assets | | |
| Property, plant and equipment | | |
| Buildings and structures, net | 15,530 | 16,220 |
| Other, net | 12,098 | 12,467 |
| Total property, plant and equipment | 27,629 | 28,687 |
| Intangible assets | | |
| In-process research and development | 4,400 | 4,400 |
| Goodwill | 14,035 | 13,592 |
| Other | 854 | 1,086 |
| Total intangible assets | 19,289 | 19,078 |
| Investments and other assets | | |
| Investment securities | 18,875 | 19,260 |
| Other | 13,251 | 12,891 |
| Total investments and other assets | 32,126 | 32,152 |
| Total non-current assets | 79,045 | 79,918 |
| Total assets | 190,422 | 176,440 |

(Millions of yen)

| | Fiscal 2024 (As of March 31, 2025) | Nine-Month period of Fiscal 2025 (As of December 31, 2025) |
|--|---------------------------------------|--|
| Liabilities | | |
| Current liabilities | | |
| Notes and accounts payable - trade | 8,186 | 9,917 |
| Electronically recorded obligations - operating | 136 | 144 |
| Short-term bank loans | 3,850 | 3,850 |
| Income taxes payable | 7,285 | 24 |
| Provision for bonuses | 1,154 | 542 |
| Other | 9,741 | 9,130 |
| Total current liabilities | 30,354 | 23,608 |
| Non-current liabilities | | |
| Provision for share-based remuneration | 163 | 141 |
| Net defined benefit liability | 4,954 | 4,945 |
| Deferred tax liabilities | 1,514 | 1,514 |
| Other | 800 | 422 |
| Total non-current liabilities | 7,433 | 7,023 |
| Total liabilities | 37,787 | 30,632 |
| Net assets | | |
| Shareholders' equity | | |
| Common stock | 23,853 | 23,853 |
| Capital surplus | 12,932 | 11,406 |
| Retained earnings | 135,242 | 124,879 |
| Treasury stock | (28,233) | (23,775) |
| Total shareholders' equity | 143,794 | 136,363 |
| Accumulated other comprehensive income | | |
| Net unrealized holding gain on securities | 6,257 | 7,047 |
| Foreign currency translation adjustment | (57) | (140) |
| Remeasurements of defined benefit plans | 2,640 | 2,538 |
| Total accumulated other comprehensive income | 8,840 | 9,444 |
| Total net assets | 152,634 | 145,808 |
| Total liabilities and net assets | 190,422 | 176,440 |

(2) Consolidated statements of income and comprehensive income
(Consolidated statements of income)
(Nine-month period of fiscal 2024 and 2025)

(Millions of yen)

| | Nine-Month period of Fiscal 2024 (April 1, 2024 – December 31, 2024) | Nine-Month period of Fiscal 2025 (April 1, 2025 – December 31, 2025) |
|--|--|--|
| Net sales | 75,990 | 57,617 |
| Cost of sales | 26,797 | 26,785 |
| Gross profit | 49,193 | 30,831 |
| Selling, general and administrative expenses | | |
| Salaries | 4,183 | 4,359 |
| Bonuses and provision for bonuses | 818 | 1,014 |
| Retirement benefit expenses | 123 | 134 |
| Research and development expenses | 10,557 | 15,645 |
| Other | 8,088 | 9,123 |
| Total selling, general and administrative expenses | 23,772 | 30,277 |
| Operating profit | 25,420 | 554 |
| Other income | | |
| Interest income | 40 | 189 |
| Dividends income | 531 | 572 |
| Foreign exchange gains | 91 | – |
| Other | 54 | 26 |
| Total other income | 717 | 788 |
| Other expenses | | |
| Interest expenses | 19 | 32 |
| Foreign exchange losses | – | 89 |
| Loss on investments in investment partnership | 20 | 33 |
| Other | 17 | 15 |
| Total other expenses | 57 | 171 |
| Ordinary profit | 26,081 | 1,172 |
| Extraordinary income | | |
| Gain on sales of investment securities | – | 862 |
| Other | 0 | 29 |
| Total extraordinary income | 0 | 891 |
| Extraordinary losses | | |
| Loss on retirement of non-current assets | 44 | 70 |
| Loss on valuation of investment securities | 15 | 2 |
| Other | 0 | 6 |
| Total extraordinary losses | 59 | 79 |
| Profit before income taxes | 26,021 | 1,984 |
| Income taxes | 6,846 | 586 |
| Profit | 19,175 | 1,398 |
| Profit attributable to owners of the parent | 19,175 | 1,398 |

(Consolidated statements of comprehensive income)
(Nine-month period of fiscal 2024 and 2025)

(Millions of yen)

| | Nine-Month period of Fiscal 2024 (April 1, 2024 – December 31, 2024) | Nine-Month period of Fiscal 2025 (April 1, 2025 – December 31, 2025) |
|--|--|--|
| Profit | 19,175 | 1,398 |
| Other comprehensive income | | |
| Net unrealized holding gain on securities | (423) | 789 |
| Foreign currency translation adjustment | – | (82) |
| Remeasurements of defined benefit plans | (61) | (102) |
| Total other comprehensive income | (484) | 604 |
| Comprehensive income | 18,690 | 2,002 |
| Total comprehensive income attributable to owners of the parent | 18,690 | 2,002 |